Acadia Pharmaceuticals | ACAD

Acadia Pharmaceuticals traded at $18.70 this Thursday March 30th, decreasing $0.28 or 1.48 percent since the previous trading session. Looking back, over the last four weeks, Acadia Pharmaceuticals lost 10.61 percent. Over the last 12 months, its price fell by 22.79 percent. Looking ahead, we forecast Acadia Pharmaceuticals to be priced at 17.66 by the end of this quarter and at 16.03 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
18.70
Daily Change
-1.48%
Yearly
-22.79%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Peers Price Day Year
Eisai 7,410.00 -44.00 -0.59% 30.69%
Acadia Pharmaceuticals 18.70 -0.28 -1.48% -22.79%
ALKERMES 27.82 -0.10 -0.36% 5.74%
Alnylam Pharmaceuticals 195.12 -0.79 -0.40% 19.49%
Aptinyx Inc 0.13 -0.002 -1.77% -94.12%
Biogen 275.13 1.12 0.41% 30.64%
BioMarin Pharmaceutical 95.29 1.09 1.16% 23.59%
Bristol-Myers Squibb 68.20 0.02 0.03% -6.61%
Cara Therapeutics 4.89 -0.19 -3.74% -59.75%
Corcept Therapeutics 21.63 -0.14 -0.64% -3.95%
Cytokinetics 34.21 -1.04 -2.95% -7.06%
Intercept Pharmaceuticals 13.48 -0.31 -2.25% -17.15%
Incyte Corp 71.04 -0.10 -0.14% -10.55%
Intra Cellular Therapies 56.05 -0.94 -1.65% -8.40%
J&J 153.43 0.12 0.08% -13.43%
Eli Lilly 340.69 4.82 1.44% 18.97%
Moderna Inc 147.44 -1.36 -0.91% -14.41%
Marinus Pharmaceuticals 6.99 0.02 0.29% -25.24%
Neurocrine Biosciences 99.21 2.11 2.17% 5.82%
Pfizer 40.38 0.13 0.32% -22.00%
Prothena 47.66 -1.55 -3.15% 30.33%
PTC Therapeutics 48.86 0.67 1.39% 30.96%
Ultragenyx Pharmaceutical 38.64 -0.43 -1.10% -46.79%
Seattle Genetics 203.08 0.85 0.42% 40.98%
Sarepta Therapeutics 136.03 -0.53 -0.39% 74.13%
Vanda Pharmaceuticals 6.71 -0.17 -2.47% -40.67%
Vertex Pharmaceuticals 312.16 -2.08 -0.66% 19.62%

Indexes Price Day Year
USND 12013 87.23 0.73% -15.52%
US2000 1768 -3.22 -0.18% -14.58%

Acadia Pharmaceuticals
Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system disorders. The Company's product pipeline includes NUPLAZID (pimavanser), Trofinetide, ACP-044 and ACP-319. NUPLAZID (pimavanserin) is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PDP). NUPLAZID is a selective serotonin inverse agonist/antagonist, preferentially targeting 5-HT2A receptors with no appreciable affinity for dopaminergic, histaminergic, or muscarinic receptors. Trofinetide is a synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 (IGF-1) designed to treat the core symptoms of Rett syndrome. ACP-044, is an orally administered, non-opioid analgesic being evaluated for the treatment of pain. ACP-319 is a positive allosteric modulator of the muscarinic receptor targeting M1 (M1 PAM).